CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 55 enrolled
Drug / intervention
PF-06751979 single ascending dose +5 moredrug
Likely dose
PF-06751979 single ascending dose 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02509117
NCT02509117Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo Controlled First-in-human Trial To Evaluate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06751979 After Oral Administration Of Single And Multiple Ascending Doses To Healthy Adult And Elderly Subjects

Pfizer·interventional·Posted Jul 27, 2015·Updated Nov 1, 2018

In Brief

A Phase 1 clinical trial evaluating PF-06751979 single ascending dose, Placebo single dose, and 3 other interventions for Healthy Subjects. Completed, enrolled 55 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 27, 2015
Enrollment StartJul 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.9 years ago

Interventions

PF-06751979 single ascending dosedrug

PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.

Placebo single dosedrug

Matched Placebo solution/suspension administered as single dose.

PF-06751979 multiple ascending dosedrug

PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.

Placebo multiple dosedrug

Matched Placebo (solution/suspension)administered daily for 14 consecutive days.

PF-06751979 multiple dosedrug

PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.

PF-06751979 multiple dosedrug

Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.